Puma Biotechnology Inc
NASDAQ:PBYI
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.25
7.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PBYI stock under the Base Case scenario is 5.41 USD. Compared to the current market price of 3.04 USD, Puma Biotechnology Inc is Undervalued by 44%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Puma Biotechnology Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PBYI cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Puma Biotechnology Inc
Balance Sheet Decomposition
Puma Biotechnology Inc
Current Assets | 137.7m |
Cash & Short-Term Investments | 96.8m |
Receivables | 28.1m |
Other Current Assets | 12.8m |
Non-Current Assets | 67.3m |
PP&E | 6.9m |
Intangibles | 56m |
Other Non-Current Assets | 4.4m |
Current Liabilities | 104.3m |
Accounts Payable | 13.5m |
Accrued Liabilities | 44.2m |
Other Current Liabilities | 46.6m |
Non-Current Liabilities | 52.2m |
Long-Term Debt | 43.7m |
Other Non-Current Liabilities | 8.5m |
Earnings Waterfall
Puma Biotechnology Inc
Revenue
|
219.1m
USD
|
Cost of Revenue
|
-59m
USD
|
Gross Profit
|
160.1m
USD
|
Operating Expenses
|
-141.2m
USD
|
Operating Income
|
18.9m
USD
|
Other Expenses
|
-10.2m
USD
|
Net Income
|
8.7m
USD
|
Free Cash Flow Analysis
Puma Biotechnology Inc
USD | |
Free Cash Flow | USD |
PBYI Profitability Score
Profitability Due Diligence
Puma Biotechnology Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Puma Biotechnology Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
PBYI Solvency Score
Solvency Due Diligence
Puma Biotechnology Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Puma Biotechnology Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PBYI Price Targets Summary
Puma Biotechnology Inc
According to Wall Street analysts, the average 1-year price target for PBYI is 4.42 USD with a low forecast of 2.02 USD and a high forecast of 7.35 USD.
Dividends
Current shareholder yield for PBYI is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 196 full-time employees. The company went IPO on 2012-03-21. The firm is focused on the development and commercialization of products to enhance cancer care. The firm's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. The company is primarily focused on the development and commercialization of the oral version of neratinib, and its advanced drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. Its other products include PB272 (neratinib, intravenous), PB357, and certain related compounds. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one PBYI stock under the Base Case scenario is 5.41 USD.
Compared to the current market price of 3.04 USD, Puma Biotechnology Inc is Undervalued by 44%.